source
- Eli Lilly to acquire AtaiBeckley for $2.8 billion, signaling deeper bet on psychedelicsEli Lilly announced on Thursday that it will acquire psychedelic drug developer AtaiBeckley. The purchase price is set at $2.8 billion paid upfront. The sizable upfront payment highlights Lilly's…
- Stakeholders urge FDA to create drug-repurposing framework that avoids disincentives and stays within authorityStakeholders, including patients and healthcare industry groups, told the FDA that repurposing existing drugs offers significant opportunities for new treatments. They warned that any new repurpos…